Kura Oncology (NASDAQ:KURA) SVP Thomas James Doyle Sells 4,539 Shares

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 4,539 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $50,746.02. Following the completion of the sale, the senior vice president directly owned 130,257 shares of the company’s stock, valued at $1,456,273.26. The trade was a 3.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Thomas James Doyle also recently made the following trade(s):

• On Monday, September 29th, Thomas James Doyle sold 4,541 shares of Kura Oncology stock. The shares were sold at an average price of $8.94, for a total transaction of $40,596.54.

Kura Oncology Trading Up 4.9%

Shares of NASDAQ:KURA traded up $0.52 on Friday, hitting $11.20. The company had a trading volume of 4,478,689 shares, compared to its average volume of 2,241,571. The firm’s 50-day simple moving average is $9.46 and its two-hundred day simple moving average is $7.48. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $16.68.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The company had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $17.48 million. On average, equities analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analyst Weigh In

KURA has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. JMP Securities restated a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a report on Monday, October 20th. Guggenheim assumed coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They issued a “neutral” rating for the company. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Friday. Finally, Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.11.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in shares of Kura Oncology by 0.9% in the third quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock worth $1,061,000 after acquiring an additional 1,039 shares during the period. E Fund Management Co. Ltd. boosted its holdings in Kura Oncology by 18.9% in the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company’s stock worth $81,000 after purchasing an additional 1,951 shares during the last quarter. Profund Advisors LLC boosted its holdings in Kura Oncology by 11.1% in the third quarter. Profund Advisors LLC now owns 24,835 shares of the company’s stock worth $220,000 after purchasing an additional 2,478 shares during the last quarter. Arizona State Retirement System raised its stake in Kura Oncology by 15.8% during the 3rd quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock valued at $181,000 after buying an additional 2,802 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Kura Oncology by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock valued at $175,000 after buying an additional 2,976 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.